Lercanidipin Accord

Lercanidipine, the active ingredient in Lercanidipin Accord, is a calcium channel blocker presented as an oral tablet for systemic use. It is prescribed to lower elevated blood pressure in adult patients with hypertension. By selectively inhibiting calcium influx in vascular smooth muscle, it promotes vasodilation and reduces peripheral resistance, helping to achieve target blood pressure levels.

GNH USA supplies Lercanidipin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is indicated for the management of hypertension, acting on the vascular smooth‑muscle calcium channels to lower blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in adults. - Primary hypertension: helps achieve guideline‑recommended blood pressure targets. - Isolated systolic hypertension: provides effective control of elevated systolic pressure.

Lercanidipine may be associated with several adverse reactions. Patients should be aware of both frequent and rare events.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after initiation. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that can cause fainting. - Hepatic dysfunction: abnormal liver enzyme elevations or hepatitis.

Before prescribing Lercanidipine, clinicians should consider several safety aspects.

- Blood pressure monitoring: check baseline and follow‑up readings to avoid excessive hypotension. - Cardiovascular assessment: evaluate for heart failure or recent myocardial infarction. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant antihypertensives: adjust doses to prevent additive blood pressure lowering. - Abrupt discontinuation: taper gradually to avoid rebound hypertension. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Concurrent use with other potent antihypertensives: risk of severe hypotension. - Grapefruit juice: enhances drug exposure and can precipitate adverse effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Diuretics: may increase risk of electrolyte imbalance. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can attenuate blood pressure‑lowering response.